Literature DB >> 26655845

Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial-Mesenchymal Transition after Resection.

Ting-Jung Wu1, Shih-Shin Chang2, Chia-Wei Li3, Yi-Hsin Hsu3, Tse-Ching Chen4, Wei-Chen Lee5, Chau-Ting Yeh6, Mien-Chie Hung7.   

Abstract

PURPOSE: Surgical resection is considered as a curative treatment modality for hepatocellular carcinoma; however, the incidence of postoperative tumor recurrence is high, leading to worse patient survival. Persistent hepatitis (inflammation) is one of the risk factors of tumor recurrence after surgical resection. The aim of this study is to investigate the underlying mechanisms linking liver inflammation to hepatocellular carcinoma progression. EXPERIMENTAL
DESIGN: In this study, we used a cytokine array to identify important cytokines whose levels are increased in liver microenvironment with severe hepatitis. We evaluated the morphologic changes, migration and invasion ability, and signal transduction in hepatocellular carcinoma cells with or without inflammatory cytokine in vitro Finally, we analyzed the NF-κB signal pathway in tumor specimens from 232 patients with hepatocellular carcinoma by immunohistochemical staining.
RESULTS: The proinflammatory cytokine TNFα was increased in the peritumoral microenvironment and contributed to tumor recurrence and metastasis. Specifically, TNFα promoted hepatocellular carcinoma cancer cell migration, invasion, and epithelial-mesenchymal transition (EMT) by upregulating the transcriptional regulator, Snail. We identified Snail as a direct target gene downstream of the TNFα-mediated canonical NF-κB activation. In addition, tumor recurrence-free survival of hepatocellular carcinoma patients correlated negatively with high p65 and Snail expression and positively with high E-cadherin expression.
CONCLUSIONS: Our results establish a signaling axis that explains how inflammatory tumor microenvironment promotes hepatocellular carcinoma recurrence and metastasis. These findings suggest that controlling liver inflammation and/or targeting NF-κB-mediated Snail expression may be a potential therapeutic strategy to prevent hepatocellular carcinoma recurrence after hepatectomy. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26655845      PMCID: PMC4818680          DOI: 10.1158/1078-0432.CCR-15-0780

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

Review 1.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

2.  Liver resection and needle liver biopsy cause hematogenous dissemination of liver cells.

Authors:  M Louha; J Nicolet; H Zylberberg; A Sabile; C Vons; G Vona; K Poussin; M Tournebize; F Capron; S Pol; D Franco; B Lacour; C Bréchot; P Paterlini-Bréchot
Journal:  Hepatology       Date:  1999-03       Impact factor: 17.425

3.  An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.

Authors:  George P Kim; Michelle R Mahoney; Daniel Szydlo; Tony S K Mok; Robert Marshke; Kyle Holen; Joel Picus; Michael Boyer; Henry C Pitot; Joseph Rubin; Philip A Philip; Anna Nowak; John J Wright; Charles Erlichman
Journal:  Invest New Drugs       Date:  2010-09-14       Impact factor: 3.850

4.  IKKα activation of NOTCH links tumorigenesis via FOXA2 suppression.

Authors:  Mo Liu; Dung-Fang Lee; Chun-Te Chen; Chia-Jui Yen; Long-Yuan Li; Hong-Jen Lee; Chun-Ju Chang; Wei-Chao Chang; Jung-Mao Hsu; Hsu-Ping Kuo; Weiya Xia; Yongkun Wei; Pei-Chun Chiu; Chao-Kai Chou; Yi Du; Debanjan Dhar; Michael Karin; Chung-Hsuan Chen; Mien-Chie Hung
Journal:  Mol Cell       Date:  2011-12-22       Impact factor: 17.970

Review 5.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

6.  Clinicopathological significance of ZEB1 protein in patients with hepatocellular carcinoma.

Authors:  Yan-Ming Zhou; Lu Cao; Bin Li; Rui-Xiu Zhang; Cheng-Jun Sui; Zheng-Feng Yin; Jia-Mei Yang
Journal:  Ann Surg Oncol       Date:  2011-05-17       Impact factor: 5.344

7.  Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1.

Authors:  Chia-Wei Li; Weiya Xia; Longfei Huo; Seung-Oe Lim; Yun Wu; Jennifer L Hsu; Chi-Hong Chao; Hirohito Yamaguchi; Neng-Kai Yang; Qingqing Ding; Yan Wang; Yun-Ju Lai; Adam M LaBaff; Ting-Jung Wu; Been-Ren Lin; Muh-Hwa Yang; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Cancer Res       Date:  2012-01-17       Impact factor: 12.701

8.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.

Authors:  K Ikeda; S Saitoh; I Koida; Y Arase; A Tsubota; K Chayama; H Kumada; M Kawanishi
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

9.  Transcriptional repressor snail and progression of human hepatocellular carcinoma.

Authors:  Keishi Sugimachi; Shinji Tanaka; Toshifumi Kameyama; Ken-ichi Taguchi; Shin-ichi Aishima; Mitsuo Shimada; Keizo Sugimachi; Masazumi Tsuneyoshi
Journal:  Clin Cancer Res       Date:  2003-07       Impact factor: 12.531

Review 10.  NF-kappaB in liver diseases: a target for drug therapy.

Authors:  Pablo Muriel
Journal:  J Appl Toxicol       Date:  2009-03       Impact factor: 3.446

View more
  9 in total

1.  IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.

Authors:  Li-Chuan Chan; Chia-Wei Li; Weiya Xia; Jung-Mao Hsu; Heng-Huan Lee; Jong-Ho Cha; Hung-Ling Wang; Wen-Hao Yang; Er-Yen Yen; Wei-Chao Chang; Zhengyu Zha; Seung-Oe Lim; Yun-Ju Lai; Chunxiao Liu; Jielin Liu; Qiongzhu Dong; Yi Yang; Linlin Sun; Yongkun Wei; Lei Nie; Jennifer L Hsu; Hui Li; Qinghai Ye; Manal M Hassan; Hesham M Amin; Ahmed O Kaseb; Xin Lin; Shao-Chun Wang; Mien-Chie Hung
Journal:  J Clin Invest       Date:  2019-07-15       Impact factor: 14.808

2.  Construction and analysis of circular RNA molecular regulatory networks in liver cancer.

Authors:  Shuangchun Ren; Zhuoyuan Xin; Yinyan Xu; Jianting Xu; Guoqing Wang
Journal:  Cell Cycle       Date:  2017-11-03       Impact factor: 4.534

3.  Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice.

Authors:  Xingkai Liu; Ping Zhang; Robert C Martin; Guozhen Cui; Guangyi Wang; Yi Tan; Lu Cai; Guoyue Lv; Yan Li
Journal:  Am J Cancer Res       Date:  2016-05-01       Impact factor: 6.166

4.  Effects of bradykinin on TGF‑β1‑induced epithelial‑mesenchymal transition in ARPE‑19 cells.

Authors:  Qingquan Wei; Qingyu Liu; Chengda Ren; Junling Liu; Wenting Cai; Meijiang Zhu; Huizi Jin; Mengmei He; Jing Yu
Journal:  Mol Med Rep       Date:  2018-02-02       Impact factor: 2.952

5.  Effects of dual plasma molecular adsorption system on liver function, electrolytes, inflammation, and immunity in patients with chronic severe hepatitis.

Authors:  Gao Chen; Mengzheng Wu; Bibo Wu; Feifei Liu; Jianying Liu; Li Liu
Journal:  J Clin Lab Anal       Date:  2019-06-17       Impact factor: 2.352

6.  Mesencephalic Astrocyte-Derived Neurotrophic Factor Inhibits Liver Cancer Through Small Ubiquitin-Related Modifier (SUMO)ylation-Related Suppression of NF-κB/Snail Signaling Pathway and Epithelial-Mesenchymal Transition.

Authors:  Jun Liu; Zhengsheng Wu; Dan Han; Chuansheng Wei; Yanyan Liang; Tongcui Jiang; Lu Chen; Manqi Sha; Yajie Cao; Fan Huang; Xiaoping Geng; Jishuang Yu; Yujun Shen; Hua Wang; Lijie Feng; Dong Wang; Shengyun Fang; Siying Wang; Yuxian Shen
Journal:  Hepatology       Date:  2020-01-26       Impact factor: 17.425

7.  Preventing Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy With Active Hexose-correlated Compound Derived From Lentinula edodes Mycelia.

Authors:  Toshiya Kamiyama; Tatsuya Orimo; Kenji Wakayama; Tatsuhiko Kakisaka; Shingo Shimada; Akihisa Nagatsu; Yoh Asahi; Takeshi Aiyama; Hirofumi Kamachi; Akinobu Taketomi
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.279

8.  Chitosan nanoparticles loaded with aspirin and 5-fluororacil enable synergistic antitumour activity through the modulation of NF-κB/COX-2 signalling pathway.

Authors:  Peng Wang; Yaping Shen; Liang Zhao
Journal:  IET Nanobiotechnol       Date:  2020-08       Impact factor: 1.847

9.  B7-Homolog 4 Promotes Epithelial-Mesenchymal Transition and Invasion of Bladder Cancer Cells via Activation of Nuclear Factor-κB.

Authors:  Haoran Wu; Xugang Wang; Naixin Mo; Liang Zhang; Xiaoliang Yuan; Zhong Lü
Journal:  Oncol Res       Date:  2018-02-01       Impact factor: 5.574

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.